SCHEMBL6995652

SCHEMBL6995652

CC1Oc2ccc(CNCc3ccc(F)cc3)cc2NC1=O

nearest known ligand 0.80

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.80
TP53 P04637 2/20 0.47
PDE3B Q13370 2/20 0.42
PDE3A Q14432 2/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SMYD3 Q9H7B4 2/20 0.42
LMNA P02545 1/20 0.41
PDGFRB P09619 1/20 0.40
KDR P35968 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302991 0.94 PARP1 (0.90) PARP1TP53PDE3BPDE3APOLB
SCHEMBL7000091 0.89 PARP1 (0.78) PARP1TP53PDE3BPDE3ASMYD3
SCHEMBL532477 0.89 PARP1 (1.00) PARP1TP53PDE3BPDE3APOLB
SCHEMBL7003151 0.89 PARP1 (0.81) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6303081 0.88 PARP1 (0.80) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6999731 0.88 PARP1 (0.80) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6305288 0.87 PARP1 (0.88) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6989623 0.86 PARP1 (0.78) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6310170 0.86 PARP1 (0.95) PARP1TP53PDE3BPDE3APOLB
SCHEMBL6998639 0.85 PARP1 (0.76) PARP1POLBSMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed